The British Business Bank has agreed a £75 million cornerstone commitment to SV Health Investors’ new flagship fund –  SV8 Biotech Fund LP – which is dedicated to multi-stage therapeutics.

It is the bank’s largest fund commitment to date and brings its total fund commitments to life sciences above half a billion, with £560m committed across 15 life science funds. 

These fund commitments have collectively leveraged £3.04 billion from private sector investors, bringing in six pounds for every one pound invested, it says.